Veru To Advance Enobosarm Into A Phase 2b Clinical Trial In Combination With Weight Loss GLP-1 Drugs Ozempic, Wegovy Or Mounjaro To Evaluate Efficacy And Safety Of Enobosarm To Further Increase Fat Loss While Preventing Muscle Wasting
Portfolio Pulse from Bill Haddad
Veru Inc. is set to advance Enobosarm into a Phase 2b clinical trial in combination with weight loss GLP-1 drugs Ozempic, Wegovy or Mounjaro. The trial aims to evaluate the efficacy and safety of Enobosarm to further increase fat loss while preventing muscle wasting.
October 04, 2023 | 12:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Veru Inc. is advancing its drug Enobosarm into a Phase 2b clinical trial. The trial will test the drug's efficacy in increasing fat loss and preventing muscle wasting when combined with weight loss drugs Ozempic, Wegovy, or Mounjaro.
The advancement of Enobosarm into a Phase 2b clinical trial is a significant step for Veru Inc. If the trial proves successful, it could potentially lead to increased revenues for the company from the sale of the drug. This could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100